Also known as: University of California San Francisco
IDT's study showed UNCOVERseq achieved 97.6% sensitivity and 78% precision for CRISPR off-target nomination. Scribe will present new data at ASGCT and EAS, including STX-1150. Watchmaker licensed CRISPR-Cas9 IP for NGS normalization.
Anthropic launched Claude Science, an AI workbench with 60+ skills and databases, and began preclinical programs for neglected diseases. A demo analyzed 100 rare genetic diseases in under an hour.
Recent studies associate blood biomarkers with brain atrophy and cognitive decline in Alzheimer's disease, while new DNA aptamers, retinal imaging, and speech analysis advance neurodegeneration detection and monitoring.
The Trump administration barred NIAID officials from WHO meetings, reclaimed $600M from four states, and faced a Senate report showing drug prices rising despite deals. New drugs average $353K a year.
ARVO named Sangeetha Kandoi and Ellen Konadu Antwi-Adjei as the 2026 recipients of its annual Advocacy Awards. The honors recognize advocacy in eye and vision research and efforts to expand equitable access to care.
Trump administration cuts to U.S. science funding have raised fears of a brain drain, with thousands of grants cancelled and researchers moving abroad. Experts warned the losses could damage biomedical innovation and the economy.
Researchers have developed new immunotherapy approaches including internal immune cell reprogramming and CD40-based therapies showing promising results in early trials. Meanwhile, glioblastoma remains resistant to current immunotherapies due to blood-brain barrier constraints, though advances in antibody engineering offer new potential strategies.
Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will depart the agency by the end of April to return to an academic role at the University of California San Francisco.
The FDA approved acalabrutinib combined with venetoclax for chronic lymphocytic leukemia and small lymphocytic leukemia based on phase III trial results. Separately, Yale researchers identified CD25 protein complex as a new drug target for aggressive leukemias.
Vie Ventures, a life sciences venture capital firm focused on autoimmune and immune-mediated diseases, announced that Jeff Bluestone, PhD, has been named Managing Director, joining founders Steven St. Peter, MD, and Luke Evnin, PhD.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779642 |
Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory Failure |
NOT_YET_RECRUITING | PHASE2 |
| NCT07774793 |
Relaxation Intervention to Improve Newborn Growth and Maternal Well-being |
NOT_YET_RECRUITING | NA |
| NCT07772310 |
The Parent Financial Stress Resilience Program |
ENROLLING_BY_INVITATION | NA |
| NCT07772297 |
Biomarkers of Cervical Spondylotic Myelopathy |
NOT_YET_RECRUITING | |
| NCT07770022 |
Validation of Biomarkers for Long COVID in the LIINC Viral Immunopathogenesis and Persistence Repeat Donor Cohort (VIPER) |
RECRUITING | |
| NCT07762612 |
"Gwan Enjoy Life:" A Peer-Supported Mental Health Mentoring Intervention to Improve Engagement in Care Among Sexual Minority Men Living With HIV in Jamaica |
NOT_YET_RECRUITING | NA |
| NCT07755748 |
Glaucoma Screening to Enhance At-Risk Californians' Health - Survey Response Incentives |
NOT_YET_RECRUITING | NA |
| NCT07749911 |
Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT) |
RECRUITING | |
| NCT07734636 |
A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury |
NOT_YET_RECRUITING | PHASE4 |
| NCT07731932 |
PNF RCT to Decrease Alcohol Use and Increase HIV Prevention |
NOT_YET_RECRUITING | NA |
